Rankings
▼
Calendar
EBS Q4 2021 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena
EBS
Emergent BioSolutions Inc.
$446M
Q4 2021 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$723M
+24.0% YoY
Gross Profit
$428M
59.1% margin
Operating Income
$277M
38.4% margin
Net Income
$189M
26.2% margin
EPS (Diluted)
$3.50
QoQ Revenue Growth
+119.8%
Cash Flow
Operating Cash Flow
$329M
Free Cash Flow
$282M
Stock-Based Comp.
$10M
Balance Sheet
Total Assets
$3.0B
Total Liabilities
$1.3B
Stockholders' Equity
$1.6B
Cash & Equivalents
$576M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$723M
$583M
+24.0%
Gross Profit
$428M
$356M
+20.2%
Operating Income
$277M
$258M
+7.5%
Net Income
$189M
$185M
+2.1%
Revenue Segments
Product
$434M
60%
Contract Development And Manufacturing
$218M
30%
Contracts and Grants
$71M
10%
Geographic Segments
UNITED STATES
$433M
66%
Non-US
$221M
34%
← FY 2021
All Quarters
Q1 2022 →